Generic Name and Formulations:
Aspirin 162.5mg; ext-rel caps.
Indications for DURLAZA:
To reduce risk of death and MI in patients with chronic coronary artery disease (eg, history of MI, unstable angina, or chronic stable angina). To reduce risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack (TIA).
Limitations Of use:
Use immediate-release aspirin if rapid onset of action is required (eg, acute MI or before PCI).
Swallow whole. Take with full glass of water at same time each day. 1 capsule once daily.
NSAID allergy. Asthma. Rhinitis. Nasal polyps.
Active peptic ulcer disease, severe hepatic or renal impairment (GFR <10mL/min); avoid. Pregnancy: avoid during 3rd trimester, 1 week prior to and during labor & delivery. Nursing mothers: not recommended.
Increased bleeding risk with anticoagulants, antiplatelets, or chronic NSAID use. Do not take 2hrs before or 1hr after consuming alcohol. Dual inhibition of the renin-angiotensin system (RAS) may increase risk of hypotension, hyperkalemia, renal impairment; monitor renal function esp. if elderly, volume depleted or compromised renal function. NSAIDs may attenuate antihypertensive effects of RAS inhibitors. May affect anticonvulsants (eg, phenytoin, valproic acid). May potentiate methotrexate; possible bone marrow toxicity esp. in elderly or renally impaired. Concomitant other NSAIDs may increase renal impairment. Ibuprofen or nonselective NSAIDs may interfere with antiplatelet effect of low-dose aspirin. Give ibuprofen 400mg at least 2–4hrs after Durlaza; wait 8hrs after ibuprofen dose before giving aspirin.
GI effects (eg, bleeding, dyspepsia, hepatic enzyme elevation, hepatitis, Reye's Syndrome), CNS effects, fluid and electrolyte imbalance, renal insufficiency and failure; fetal toxicity, salicylate toxicity.
Ext-rel caps—30, 90
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|